Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
about
Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neuronsDistinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatumImmunohistochemical localization of phosphodiesterase 2A in multiple mammalian speciesEvaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverinePhosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical ImplicationsPhosphodiesterases in neurodegenerative disordersStructural insight into substrate specificity of phosphodiesterase 10Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMPIdentification and Optimization of PDE10A Inhibitors Using Fragment-Based Screening by Nanocalorimetry and X-ray CrystallographyStriatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicityHPRT-deficiency dysregulates cAMP-PKA signaling and phosphodiesterase 10A expression: mechanistic insight and potential target for Lesch-Nyhan Disease?TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple ParadigmsInhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical StimulationRadiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primateEffects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profilePhosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in StriatumReview: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibitionPhosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implicationsApproaches and tools for modeling signaling pathways and calcium dynamics in neuronsInhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's diseaseModulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.Striatal neurodevelopment is dysregulated in purine metabolism deficiency and impacts DARPP-32, BDNF/TrkB expression and signaling: new insights on the molecular and cellular basis of Lesch-Nyhan Syndrome.Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia.Inhibition of phosphodiesterase10A attenuates morphine-induced conditioned place preference.Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activityThe distribution of phosphodiesterase 2A in the rat brain.Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subjectNovel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder.A novel thermoregulatory role for PDE10A in mouse and human adipocytesRadiosynthesis and Radiotracer Properties of a 7-(2-[18F]Fluoroethoxy)-6-methoxypyrrolidinylquinazoline for Imaging of Phosphodiesterase 10A with PET.The NO/cGMP pathway inhibits transient cAMP signals through the activation of PDE2 in striatal neurons.Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine] in rats: potRadiosynthesis and biological evaluation of the new PDE10A radioligand [18 F]AQ28A.Potential drug targets and treatment of schizophrenia.FACS purification of immunolabeled cell types from adult rat brain.Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation.Modeling spatial aspects of intracellular dopamine signaling.
P2860
Q21131062-FF9F794D-E5B4-472B-84AA-04DE25320F5CQ23909635-2AC6FF50-CDC6-4B24-AC7A-B26C75C4FA74Q24337499-8964F452-0278-48C2-A0AC-42FEF0017537Q24649503-424DC802-953D-4C71-945C-981FA9F72A38Q26753116-E552B99E-53FB-4855-8C13-54F9B2B3BE85Q27026359-B7365AD4-CC06-47DE-82A9-E4C3B007A001Q27644254-5FABB0EF-8608-4E9F-9870-63B3E9B6A03BQ27650596-10E5F80F-F125-4405-945E-782C5389D1B9Q27681131-2BACD175-957F-4C4B-A12C-BC01256E7D16Q28239309-4A7D01A3-A20E-4382-A294-4BB78DF0C4C8Q28382961-E7AA8AC1-7255-4152-82F8-C038221F4978Q28384192-DC923D60-2EBF-4E8A-9137-115F30F928B9Q28387521-19EBCB97-BDB1-4657-AC90-4539ADFAF04BQ28387761-FCC609DD-D847-4F15-8034-5C9C81833555Q28389666-5B48DB06-F19D-4522-A12D-462AE7F70AA6Q28393596-F0FDBE3C-B7C2-4969-9122-64D36BF76862Q28394979-54857A0C-8AD7-42A5-9C03-6B595B346082Q28396609-4C683041-C3AC-40B9-9E33-9E012C5DCE14Q28535192-333A365A-1E4A-4455-A9BB-4C4FDCD0B05FQ28748849-7992A16C-8D1C-4E8A-8AB3-6B161D00E23CQ30391868-4AF81AC0-6592-40FA-98F6-9E3622DAC4A6Q33578074-9E990CAE-7A62-42F5-A892-01DAB7DB2510Q33624262-EAC4B5EF-C32A-43DC-9075-2B938280C72DQ33831774-F75D4819-13B5-400B-A2FC-A4467E8573F5Q34103482-52C4D658-2801-44A0-80FA-839C3726C257Q34268331-3769C22C-4CE5-4644-9999-CABC984AF2FAQ34416260-CDE2FA0B-C940-46E5-AACF-D2A48542EE47Q35538783-FC6A70C2-199F-4B3B-89E9-D20D4C55B152Q36157209-72F039E0-DA53-4E8B-BC9F-13649B5270EBQ36915473-E2959D87-17AC-45D9-8F99-D1E7F0A1B0F8Q37061111-A33C6565-132F-4205-8132-949F52326DF4Q37148692-231341F5-C8B1-48F0-9A96-3D3A30A0A42DQ37317832-3AFA3FF6-45A1-4A40-A043-BDD97D279048Q37591807-1804BA05-C7D3-47D8-8DEC-0ED5A378B6B4Q39146304-032A5DED-D776-4BC3-9EBA-275A6981663AQ39206300-9C5C2AE9-3081-4B3E-80F7-73163D364EEDQ39292022-61A9FA6B-A38A-4E86-8BA5-4534385AABA4Q39819933-2D72AC0F-1845-4E24-8442-5953DE487236Q40424916-FDD6FDBD-5411-40A8-89D4-810B4A4E0078Q41558837-007B8384-AC0C-481A-B19D-17EDAF3605D9
P2860
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
description
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im Mai 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/05/12)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/05/12)
@nl
наукова стаття, опублікована в травні 2006
@uk
مقالة علمية (نشرت في 12-5-2006)
@ar
name
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@ast
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@en
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@nl
type
label
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@ast
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@en
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@nl
prefLabel
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@ast
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@en
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@nl
P2093
P2860
P3181
P1433
P1476
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
@en
P2093
A. B. Jakowski
C. A. Strick
D. G. Morton
D. T. Stephenson
F. S. Menniti
R. D. Williams
R. J. Kleiman
W. D. Eldred
W. O. Adamowicz
P2860
P304
P3181
P356
10.1016/J.NEUROSCIENCE.2005.12.042
P407
P577
2006-05-12T00:00:00Z